Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.
Lorenz
Raymond A
RA
Weinstein
Benjamin
B
D000328:Adult; D018692:Antimanic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068180:Aripiprazole; D001714:Bipolar Disorder / Q000188:drug therapy; D002998:Clonazepam / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006177:Gynecomastia / Q000139:chemically induced; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011388:Prolactin / Q000097:blood / Q000187:drug effects; D015363:Quinolones / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D002998:Clonazepam; D014635:Valproic Acid; D000068180:Aripiprazole; D011388:Prolactin; C033563:haloperidol decanoate; D006220:Haloperidol